Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 12/20 | 0.56 |
| ▸ | CCNK | O75909 | 2/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.49 |
| ▸ | CDK9 | P50750 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911322 | 0.87 | USP7 (0.73) | USP7CDK12CCNT1CDK9 | |
| SCHEMBL23921895 | 0.87 | USP7 (0.73) | USP7CDK12CCNT1CDK9 | |
| SCHEMBL23921892 | 0.87 | USP7 (0.73) | USP7CDK12CCNT1CDK9 | |
| SCHEMBL23911239 | 0.87 | USP7 (0.56) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910957 | 0.87 | USP7 (0.56) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910700 | 0.87 | USP7 (0.55) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23911640 | 0.86 | USP7 (0.76) | USP7CCNKCDK12 | |
| SCHEMBL23911635 | 0.85 | USP7 (0.54) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910772 | 0.85 | USP7 (0.53) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910995 | 0.83 | USP7 (0.55) | USP7CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885CCNK 2280/4885CDK12 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.